Thrilled to announce that our SNIP paper is live Cell! SNIP is a high-performance drug-regulated CAR platform that is optimized for the clinic--plans for a trial are already underway Stanford Medicine. #CART #Immunotherapy #SynBio #Cancer. sciencedirect.com/science/articl… 1/

Our new cell type classification method for image data is out! Congrats to Stanford Plevritis Lab and Wei especially!

So grateful to become a part of the Irving Cancer Immunology community! Thanks to Sandra & Arthur Irving, Nir, Bob, and rest of the team to enable trainees connect and stellar mentorship we received.

Check out this new study from Stanford showing expanded CAR Tregs infusion correlate with poorer disease control and less neurotoxicity: rdcu.be/cVrjr A new axis for manipulation to improve outcomes for patients! #StanfordCCT #MackallLab #CARTregs

Research by #PICINetwork members Mackall Lab and Zinaida Good Stanford Medicine, with Jay Spiegel and others, could inform the design of next-generation CAR T cell therapies.

Single-cell proteomic profiling of circulating #CART cells in patients treated with CD19-CAR shows that CD4+Helios+ CAR #Treg cells on day 7 after infusion are associated with progressive disease & less severe neurotoxicity in patients with #LBCL. nature.com/articles/s4159…

In collaboration with Parker Institute for Cancer Immunotherapy scientists and 10x Genomics, we wrote a commentary on "Advancing T cell–based cancer therapy with single-cell technologies" just out in Nature Medicine: rdcu.be/cVXK8

To accelerate development of effective T cell therapies for cancer, there's an urgent need to decipher the attributes of the ideal therapeutic T cell Read the Meeting Report from the Parker Institute & 10x Genomics Samantha Bucktrout Parker Institute for Cancer Immunotherapy 10x Genomics nature.com/articles/s4159…

Thanks to STAT for covering our work identifying CAR Treg cells as limiting efficacy, toxicity, and expansion of CD19-CAR in lymphoma. Full article in Nature Medicine here: rdcu.be/cVqVr. statnews.com/2022/10/04/why…

Thanks Teiko bio for highlighting our work with Jay Spiegel, Bita Sahaf, Mackall Lab, David Miklos, and team on defining the role of CAR Treg cells in progression following #CART therapy for lymphoma.

Honored to be interviewed by 10x Genomics to discuss our work with Sneha Ramakrishna , Mackall Lab, and Michelle Monje🎗️ on GD2-CAR T cell therapy for pediatric brain cancer.

Grateful to CGTLive® to publish this summary of our work with Mackall Lab, David Miklos, Bita Sahaf and team that I presented at AACR! cgtlive.com/view/lineage-t…

Humbled and grateful to be selected as a 2023 Bridge Fellow by the Parker Institute for Cancer Immunotherapy to push forward CAR T immunotherapy research. parkerici.org/the-latest/ecr…

Grateful to give an invited talk at the 6th Annual #Treg-Directed Therapies Summit! Please join us in Boston this May 21-23. treg-directed-therapies.com

Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scientific society and impact every aspect of a VC firm, serving unprecedented ideas, scientists and engineers. Join boomcap.co and apply here:

Our Stanford Center for Cancer Cell Therapy is excited to offer a Postdoctoral Fellow position at the interface between machine learning and T cell therapies: postdocs.stanford.edu/prospective/op…